Michelle Pratt, a dermatologist in St. John’s, took extensive precautions to safeguard her premature twin sons, born at 32 weeks and four days, against the respiratory syncytial virus (RSV), a common and highly contagious virus causing respiratory tract infections in infants. Concerned after friends’ children were hospitalized for RSV, Pratt delved into medical research during her pregnancy, focusing on recommendations from expert groups like the Canadian Pediatric Society and the National Advisory Committee on Immunization (NACI).
Following Health Canada’s approval in April 2023, Pratt learned about nirsevimab, also known as Beyfortus, a monoclonal antibody considered the primary prevention for severe RSV in newborns and young infants. A single-dose administered shortly after birth, nirsevimab offers protection for approximately five months. Subsequently, a new bivalent vaccine, Abrysvo, was approved for pregnant individuals between 32 and 36 weeks of gestation to safeguard infants for the first six months after birth.
In 2024, NACI recommended provinces to progress towards a universal RSV immunization program for all infants. While most provinces have adopted this recommendation to various extents, Newfoundland and Labrador, Alberta, British Columbia, and New Brunswick only provide coverage to high-risk infants, excluding Pratt’s sons due to their premature birth timing.
Health professionals advocate for broader access to RSV preventive measures, emphasizing the severe implications of RSV on infants. Dr. Shelley Ross, a vocal advocate, believes these preventive measures have significantly reduced hospitalizations and ICU admissions, calling it a highlight in medical advancements.
Despite positive outcomes in provinces like Ontario and Quebec where coverage is comprehensive, Newfoundland and Labrador lags, with no concrete plans to expand coverage. RSV cases have been rising, prompting calls for universal access programs to ensure all infants receive necessary protection. Private purchase options, though available, come at a high cost, making universal access a pressing concern for many families.
Pratt, who opted to privately purchase protection for her sons, stresses the importance of equitable access to RSV preventive measures, advocating for a universal access program to safeguard all infants. She believes the upfront cost for public health will ultimately save on costly hospitalizations in the long run, emphasizing the need for fair and accessible healthcare for all infants.
